FULL PRESCRIBING INFORMATION

Contact us

Corporate Headquarters and Immunotherapy Manufacturing Facility:

1700 Saturn Way
Seal Beach, CA 90740
Phone: 877-256-4545

Immunotherapy Manufacturing Facility:

6715 Oakley Industrial Blvd
Union City, GA 30291

Medical and Operations:

1208 Eastlake Avenue East
Seattle, WA 98102

Phone: 877-336-3736

Select option 3 to speak with one of our Medical Information Specialists

For more information please contact the appropriate department:

Product and Patient Information:

Phone: 877-336-3736
Fax: 877-556-3737

Medical Information Request:

To request additional information or to submit a request for specific data, register at dendreonmedicalaffairs.com

Phone: 877-336-3736

Select option 3 to speak with one of our Medical Information Specialists

Employment:

Phone: 877-256-4545

To learn more about opportunities, visit dendreon.com/join-us

INDICATION

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia.

Thromboembolic Events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular Disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is not tested for transmissible infectious diseases.

Concomitant Chemotherapy or Immunosuppressive Therapy: Chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or PROVENGE has not been studied. Concurrent use of immune-suppressive agents may alter the efficacy and/or safety of PROVENGE.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Full Prescribing Information.